Sugi Predict

Sugi Predict / Compounds / SCHEMBL4689872

SCHEMBL4689872

SCHEMBL4689872

CC(O)c1cnc(Cl)nc1Cl

nearest known ligand 0.32

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ PDE2A O00408 1/20 0.32
▸ CSNK1A1 P48729 1/20 0.31
▸ CLK4 Q9HAZ1 1/20 0.31
▸ JUN P05412 1/20 0.30
▸ NFKB1 P19838 1/20 0.30
▸ NFKB2 Q00653 1/20 0.30
▸ RELA Q04206 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4706546 0.83 APLNR (0.31) KDM4EALDH1A1SMN1; SMN2PDE2A
SCHEMBL1428249 0.82 KDM4E (0.34) KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4
SCHEMBL30325973 0.81 JUN (0.38) KDM4EALDH1A1SMN1; SMN2PDE2AJUN
SCHEMBL24122433 0.81 JUN (0.38) KDM4EALDH1A1SMN1; SMN2PDE2AJUN
SCHEMBL4689683 0.80 KDM4E (0.36) KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4
SCHEMBL19749068 0.80 KDM4E (0.32) KDM4ECSNK1A1CLK4JUNNFKB1
SCHEMBL24101193 0.79 KDM4E (0.38) KDM4EALDH1A1SMN1; SMN2
SCHEMBL4706130 0.79 LMNA (0.33) KDM4EALDH1A1SMN1; SMN2PDE2AJUN
SCHEMBL4689680 0.78 KDM4E (0.32) KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4
SCHEMBL14290380 0.78 KDM4E (0.32) KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459927-B2 Plasma kallikrein inhibitors MERCK SHARP & DOHME LLC (US) 2025-11-04 — — US disclosed
WO-2025076284-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME DELPHIA THERAPEUTICS, INC. (US) 2025-04-10 — — WO disclosed
CN-115989224-B Plasma kallikrein inhibitors 默沙东有限责任公司 2025-02-25 — — CN disclosed
WO-2024044731-A1 DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY MATCHPOINT THERAPEUTICS INC. (US) 2024-02-29 — — WO disclosed
WO-2024044731-A1 DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY MATCHPOINT THERAPEUTICS INC. (US) 2024-02-29 — — WO disclosed
US-20230286958-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-09-14 — — US disclosed
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 — — US disclosed
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 — — US disclosed
EP-4164634-A1 PLASMA KALLIKREIN INHIBITORS Merck Sharp & Dohme LLC (US) 2023-04-19 — — EP disclosed
CN-115989224-A Plasma kallikrein inhibitors 默沙东有限责任公司 2023-04-18 — — CN disclosed
US-7129351-B2 Pyrimido compounds having antiproliferative activity HOFFMANN-LA ROCHE INC. (US) 2006-10-31 — — US disclosed
US-7112676-B2 Pyrimido compounds having antiproliferative activity HOFFMANN-LA ROCHE INC. (US) 2006-09-26 — — US disclosed
WO-2005121107-A1 PYRAZOLO PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2005-12-22 — — WO disclosed
US-20050277655-A1 e.g. [3-(2-Methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl-amine; cyclin-dependent kinase (Cdk1, 2, 4) inhibitor; anticarcinogenic agent; breast, lung, colon and prostate solid tumors DING QINGJIE 2005-12-15 — — US disclosed
EP-1560829-A1 PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY (II) F. HOFFMANN-LA ROCHE AG (CH) 2005-08-10 — — EP disclosed
EP-1560832-A1 PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2005-08-10 — — EP disclosed
US-20050075272-A1 Pyrimido compounds having antiproliferative activity DERMATAKIS APOSTOLOS (US) 2005-04-07 — — US disclosed
US-20040110773-A1 Pyrimido compounds having antiproliferative activity HOFFMANN-LA ROCHE INC. 2004-06-10 — — US disclosed
WO-2004041821-A1 PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY (II) F. HOFFMANN-LA ROCHE AG (CH) 2004-05-21 — — WO disclosed
WO-2004041822-A1 PYRIMIDO[4,5-D]PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2004-05-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075272-A1 Pyrimido compounds having antiproliferative activity LCK, FGFR1, FYN KDM4E 1120/4885ALDH1A1 1457/4885SMN1; SMN2 1764/4885
US-20230286958-A1 PLASMA KALLIKREIN INHIBITORS KLKB1, SERPINE1, KLK5 KDM4E 1074/4885ALDH1A1 1701/4885SMN1; SMN2 4669/4885
US-20050277655-A1 e.g. [3-(2-Methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl-amine; cyclin-dependent kinase (Cdk1, 2, 4) inhibitor; anticarcinogenic agent; breast, lung, colon and prostate solid tumors CDK1, CDK4, CDK2 KDM4E 743/4885ALDH1A1 2766/4885SMN1; SMN2 3338/4885
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR3, LPAR1, LPAR2 KDM4E 2137/4885ALDH1A1 2326/4885SMN1; SMN2 4532/4885
US-12459927-B2 Plasma kallikrein inhibitors KLKB1, SERPINE1, KLK5 KDM4E 1074/4885ALDH1A1 1701/4885SMN1; SMN2 4669/4885
US-20040110773-A1 Pyrimido compounds having antiproliferative activity SRC, LYN, TK1 KDM4E 2418/4885ALDH1A1 2653/4885SMN1; SMN2 1301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.